Hilleman Laboratories invests $80m in vaccine development hub

The new facility is the first of its kind in Singapore.

Hilleman Laboratories established a new vaccine development and manufacturing hub on 6 December. The project is supported by the Singapore Economic Development Board (EDB).

The hub will comprise a 30,000-square-foot current Good Manufacturing Practices (cGMP) facility at 138 Depot Road and a state-of-the-art research and development facility at Biopolis, which began operations in April 2021.

The company will invest close to $80m (US$58m) in operations, infrastructure, and capacity building over the next five years.

"Singapore is an important base for Hilleman Laboratories to expand in the region and beyond as we ramp up efforts to develop timely, novel, and affordable vaccines and biologics for infectious diseases, which exert a heavy burden on low- and middle-income countries. EDB's support strengthens our position as an end-to-end development organisation whilst lending our expertise in vaccines and biologics to build local capabilities to address urgent public health challenges caused by vaccine-preventable diseases, some of which have pandemic potential,” said CEO Raman Rao.

Hilleman Laboratories plans to leverage the local ecosystem in hiring up to 50 scientists, engineers, and managers in Singapore, offering training and career development opportunities and equipping them with the skills and expertise necessary to strengthen the country's capabilities in the development of vaccines and biologics, in compliance with global regulatory and quality standards.

Follow the link s for more news on

Economic Development Board Singapore

Hilleman Laboratories

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia